Liposomal Amphotericin B in the Treatment of Fungal Infections
1986; American College of Physicians; Volume: 105; Issue: 1 Linguagem: Inglês
10.7326/0003-4819-105-1-130
ISSN1539-3704
Autores Tópico(s)Antifungal resistance and susceptibility
ResumoEditorials1 July 1986Liposomal Amphotericin B in the Treatment of Fungal InfectionsGABRIEL LOPEZ-BERESTEIN, M.D.GABRIEL LOPEZ-BERESTEIN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-105-1-130 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe successful development of drug carriers as tools to enhance the therapeutic index of known active drugs will depend on the appropriate selection of drug, drug carrier, and disease target. The use of liposomes as carriers for amphotericin B illustrates the feasibility of such an approach. Amphotericin B, a polyene antibiotic, is the mainstay of therapy for most systemic fungal infections and is also an effective agent for treating leishmaniasis. Its use is limited, however, by its severe acute and chronic side effects, particularly acute fever, chills, and electrolyte disturbances. Chronic administration of the drug leads invariably to decreased kidney...References1. HAMILTON-MILLER J. Chemistry and biology of the polyene macrolide antibiotics. Bacteriol Rev. 1973;37:166-96. CrossrefGoogle Scholar2. BANGHAM A. Development of the liposome concept. In: GREGORIADIS G, ALLISON AC, eds. Liposomes in Biological Systems. New York: John Wiley & Sons; 1980:1-24. Google Scholar3. LOPEZ-BERESTEIN G, MEHTA R, HOPFER R, MEHTA K, HERSH E, and JULIANO R. Effects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasis. Cancer Drug Deliv. 1983;1:37-42. CrossrefMedlineGoogle Scholar4. LOPEZ-BERESTEIN G, MEHTA R, and HOPFER R. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis. 1983;147:939-44. CrossrefMedlineGoogle Scholar5. LOPEZ-BERESTEIN G, HOPFER R, MEHTA R, MEHTA K, HERSH E, and JULIANO R. Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice. J Infect Dis. 1984;150:278-83. CrossrefMedlineGoogle Scholar6. LOPEZ-BERESTEIN G, KASI L, and ROSENBLUM M. Clinical pharmacology of 99mTc-labeled liposomes in patients with cancer. Cancer Res. 1984;44:375-8. MedlineGoogle Scholar7. LOPEZ-BERESTEIN G, ROSENBLUM M, and MEHTA R. Altered tissue distribution of amphotericin B by liposomal encapsulation: comparison of normal mice to mice infected with Candida albicans. Cancer Drug Deliv. 1984;1:199-205. CrossrefMedlineGoogle Scholar8. CHRISTIANSEN K, BERNARD E, GOLD J, and ARMSTRONG D. Distribution and activity of amphotericin B in humans. J Infect Dis. 1985;152:1037-43. CrossrefMedlineGoogle Scholar9. MEHTA R, LOPEZ-BERESTEIN G, HOPFER R, MILLS K, and JULIANO R. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim Biophys Acta. 1984;770:230-4. CrossrefMedlineGoogle Scholar10. LOPEZ-BERESTEIN G, FAINSTEIN V, and HOPFER R. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis. 1985;151:704-10. CrossrefMedlineGoogle Scholar11. MAYHEW E, RUSTUM Y, and VAIL W. Inhibition of liver metastases of M5076 tumor by liposome-entrapped Adriamycin. Cancer Drug Deliv. 1983;1:43-58. CrossrefMedlineGoogle Scholar12. ALVING C, STECK E, HANSON W, LOIZEAUX P, CHAPMAN W, and WAITS V. Improved therapy of experimental leishmaniasis by use of a liposome-encapsulated antimonial drug. Life Sci. 1978;22:1021-6. CrossrefMedlineGoogle Scholar13. FIDLER I, SONE S, FOGLER W, and BARNES Z. Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci USA. 1981;78:1680-4. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: GABRIEL LOPEZ-BERESTEIN, M.D. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byCentral Retinal Artery Occlusion in COVID-Associated MucormycosisCentral retinal artery occlusion as the presenting manifestation of invasive rhino-orbital-cerebral mucormycosisEnhancement of repair of UV damage in humansInhalational interleukin-2 liposomes for pulmonary metastases: a phase I clinical trialNative lung pneumonectomy for invasive pulmonary aspergillosis following lung transplantation: a case reportAspergillus fumigatus and AspergillosisRECENT PROGRESS AND CURRENT PROBLEMS IN TREATMENT OF INVASIVE FUNGAL INFECTIONS IN NEUTROPENIC PATIENTSSUCCESSFULLY TREATED INVASIVE PULMONARY ASPERGILLOSIS ASSOCIATED WITH SMOKING MARIJUANA IN A RENAL TRANSPLANT RECIPIENTVisceral leishmaniasis in HIV infected patients: Treatment with high dose liposomal amphotericin B (AmBisome)Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapyNew antifungal compounds and strategies for treatment of invasive fungal infections in patients with neoplastic diseasesDose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosisCytokines in liposomes: Preliminary studies with IL-1, IL-2, IL-6, GM-CSF and interferon-γAspergillose pulmonaire invasive: intérêt d'un traitement par amphotéricine B intraveineuse administrée dans une émulsion triglycéridique à usage parentéralCritical Appraisal of Antimicrobials for Prevention of Infections in Immunocompromised HostsAmphotericin B and its delivery by liposomal and lipid formulationsInvasive Fungal Infections: Problems and Challenges for Developing New Antifungal CompoundsThe child with cancer and infection. II. Nonbacterial infectionsLow-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantationEffect of salt supplementation on amphotericin B nephrotoxicityRhinocerebral mucormycosis: Use of liposomal amphotericin BCardiopulmonary Toxicity after Liposomal Amphotericin B InfusionStewart J. Levine, MD, Thomas J. Walsh, MD, Anthony Martinez, MD, Peter Q. Eichacker, MD, Gabriel Lopez-Berestein, MD, Charles Natanson, MDDrug Targeting in Cancer Chemotherapy: A Clinical PerspectiveImprovement of amphotericin B activity during experimental cryptococcosis by incorporation into specific immunoliposomesPharmacokinetic Study of Liposome-Encapsulated Human Interferon-γ after Intravenous and Intramuscular Injection in MiceAspergillosisHongos y patologia respiratoria en nuestro medioLes antimycosiques en 1988Recent developments in prophylaxis and therapy of invasive fungal infections in granulocytopenic cancer patients 1 July 1986Volume 105, Issue 1Page: 130-131KeywordsAmphotericinAntibioticsDrug administrationDrugsFeversFungal diseasesInfectious diseasesKidneysLeishmaniasisLiposomes ePublished: 1 December 2008 Issue Published: 1 July 1986 PDF downloadLoading ...
Referência(s)